Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801348 | 0.91 | PPARG (0.68) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5503225 | 0.88 | PPARG (0.51) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29196231 | 0.88 | PPARG (0.56) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30754090 | 0.87 | CYP4A11 (0.54) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29196220 | 0.86 | PPARG (0.55) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2742567 | 0.86 | TSHR (0.61) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27348978 | 0.86 | PPARG (0.50) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3963370 | 0.85 | PPARA (0.78) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26270868 | 0.85 | MAPT (0.51) | PPARGPPARANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22109001 | 0.84 | PPARG (0.56) | PPARGPPARANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371811-B1 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8575134-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2592066-A1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-1826197-B1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | PPARG 1967/4885PPARA 1476/4885NPC1 1102/4885 |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | PPARG 1967/4885PPARA 1476/4885NPC1 1102/4885 |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | EDNRA, EDNRB, S1PR1 | PPARG 1967/4885PPARA 1476/4885NPC1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.